Phase III clinical trial - Sein métastatique HER2+

DS8201-A-U301 (DESTINY- Breast02)
Sein métastatique HER2+
Essai clinique fermé
Public cible
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1.
Description de l'essai
This study will compare DS 8201a to standard treatment.;Participants must have HER2 breast cancer that has been treated before.;Their cancer:;Àcannot be removed by an operation;Àhas spread to other parts of the body